RELEASE TIME：2026-10-23ARTICLE SOURCE:elravie艾莉薇
October 22, 2026 – Beijing Jingzhi Pharmaceutical Technology Co., Ltd. and Korea Humedix Co., Ltd. have officially renewed the exclusive distribution agreement for Elravie® Sodium Hyaluronate Gel for Injection in China. This renewed partnership not only ushers in a new era for both parties but also further solidifies Jingzhi Pharmaceutical's strategic role as a long-term "brand co-builder" for Elravie in the Chinese market. Forged over a decade, we move forward with certainty. Looking ahead, both parties will continue to jointly drive a new ecosystem in the medical aesthetics industry. By empowering professional aesthetics through technological innovation, we aim to continuously enhance Elravie’s brand influence and consumer mindshare in the mid-to-high-end hyaluronic acid segment. Furthermore, in response to consumers' evolving demands, we will introduce richer and more diverse aesthetic solutions.
The signing ceremony was held at the Huons Group headquarters in Pangyo, South Korea. Li Jing, Chairman of Beijing Jingzhi Pharmaceutical Technology Co., Ltd., and Zhang Lei, General Manager, alongside key Korean representatives, attended the ceremony and signed the cooperation agreement on behalf of their respective companies. Since first joining hands in 2015, Jingzhi Pharmaceutical and Humedix have maintained an exclusive distribution partnership for ten consecutive years—a rare achievement in the Chinese medical aesthetics market. This milestone demonstrates that Jingzhi Pharmaceutical has long transcended the traditional role of a distributor. Today, we are deeply integrated into Elravie’s success in China, serving as a "co-builder" in brand development, marketing, product iteration, and academic exchange.
Leveraging a decade of brand heritage, omni-channel presence, and a stellar reputation, Elravie has established strong professional recognition and deep consumer trust in the Chinese market. The brand operates a robust system of regular aesthetic training and medical exchange programs, continuously promoting standardized injection practices across the industry. On the consumer-facing front, Elravie actively builds brand loyalty through diversified marketing strategies. Notably, the brand was honored with the "Consumer Favorite Brand of the Year 2025" by Meituan Trusted Beauty, winning the hearts of a vast consumer base with its trustworthy, compliant, and empathetic brand image.
Elravie has always been rooted in technological iteration and product innovation. From the first-generation "Classic"—the first monophasic hyaluronic acid approved in China—to the widely acclaimed "Legend" and "Fashion Style" series known for their volumizing and shaping capabilities, each product has become a market sensation. In 2024, the brand launched the upgraded Elravie-A® and Elravie-M® product portfolio, incorporating new AMD cross-linking technology and SPT purification processes. This clearly establishes a combined treatment advantage of "bony support + dynamic filling," seamlessly integrating the concept of precision layered anti-aging with superior product efficacy. It provides medical aesthetic institutions and injecting physicians with precise, systematic combination treatment solutions. Looking ahead, Jingzhi Pharmaceutical plans to introduce the premium Elravie Volumizing series, unlocking the full potential of the Elravie family for comprehensive aesthetic shaping.
Rooted in a decade-long journey, this renewed agreement marks both a new milestone and a declaration of Jingzhi Pharmaceutical's commitment to unlocking future value. For the industry and our partners, we will continue to uphold a stable long-term philosophy built on "Product + Technology + Communication + Trust." Together with more medical aesthetic institutions, we will integrate the full Elravie product line into routine practice planning to navigate market dynamics, reinforcing that technological innovation and product strength remain the brand's core competencies. Simultaneously, we will continue to build a trustworthy brand image for consumers, guiding them toward beauty decisions rooted in natural aesthetics.
A decade is a journey of mutual growth, as well as an opportunity and a challenge facing the future. Beijing Jingzhi Pharmaceutical Technology Co., Ltd. and Humedix Co., Ltd. will continue to leverage the Elravie brand as our bond, quality as our founding principle, and products as our foundation. With the mindset of long-termists, we will persistently drive the integration of technological innovation and professional aesthetics, empowering continuous brand value elevation. Meanwhile, both parties will walk side by side with more industry partners, exploring broader possibilities in the medical aesthetics field through channel co-building, ecosystem integration, and value sharing—collectively driving the upward momentum of the entire industry.
